Mhairi Copland

Has grant

Professor of Translational Haematology

University of Glasgow

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mhairi Copland is a Professor of Translational Haematology at the University of Glasgow, UK. Her research focuses on chronic myeloid leukaemia (CML) and hematologic malignancies, exploring various treatment strategies and the underlying biological mechanisms. Recent articles include studies on leukaemic stem cells, mitochondrial metabolism, and the bone marrow immune microenvironment, contributing to advancements in targeted therapies and treatment outcomes.

Recent Grants

Grant: Close

Targeting p53, c-Myc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CML

Open Date: 2015-06-01

Close Date: 2020-05-01

Grant: Close

Leukaemia and Lymphoma Research Therapy Acceleration Programme

Open Date: 2012-07-01

Close Date: 2016-12-01

Grant: Close

Targeting abnormal control of cell division and quiescence to eliminate leukaemia stem cells

Open Date: 2011-07-01

Close Date: 2015-06-01

Grant: Close

An investigation of the control of cell division and quiescence in leukaemic versus normal haemopoietic stem and progenitor cells

Open Date: 2009-04-01

Close Date: 2010-03-01

Grant: Close

An investigation of the control of cell division and quiescence in leukaemic versus normal haemopoietic stem and progenitor cells

Open Date: 2009-04-01

Close Date: 2013-03-01

Articles (19)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

UNITED KINGDOM

View details

Senior Lecturer in Cancer Research

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mhairi Copland

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial

Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy

Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.

Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities

Recommendations for laboratory testing of UK patients with acute myeloid leukaemia

Targeting BCR-ABL1-positive leukaemias: a review article

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity

Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Collaborators (10)

Helen Wheadon

Simon Rogers

Robert Hills

Shaun Patterson

David Sumpton

Bodhayan Prasad

Andrew Wilson

Emma Searle

Sylvie Freeman

G Vignir Helgason

Make your next move.